In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

The surprise move is a major victory for compounding pharmacists and patients who were furious with the FDA after its announcement on Oct. 2 that the tirzepatide shortage was resolved. Shortages ...

FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now By Robin Foster HealthDay Reporter TUESDAY, Oct. 15, 2024 (HealthDay News) -- Pharmacists may continue making ...